Agios-INDIGO (AG881-C-004) Recurrent Gr.2 Glioma (Age 12 and Up) - Clinical Trial

We are doing this study to learn more about the safety and usefulness of the study drug (AG88) in people with residual or recurrent Grade 2 glioma that have an IDH1 or IDH2 mutation.

Brain Tumor (Grade II Glioma)

Children, 12+ and Adults who have:
-Recurrent or residual Grade II oligodendroglioma OR an Astrocytoma brain tumor
-IDH1 or IDH2 mutation
-Have had surgery at least 1 time, 1-5 years ago
-Not had anticancer therapy before
-No major heart disease in last 6 months
-No immediate need for Radiation or Chemotherapy

If you choose to join this study, you will:
-Be randomized (like flipping a coin) to Group 1 or Group 2
--Group 1 will get the study drug (AG881)
--Group 2 will get a placebo (harmless pill that does not treat anything)
*The randomization is double blinded, which means that the patients, their doctors and the study team will not know which group you will be in.

BOTH Groups will:
-Take the pill assigned to them for a 28 day cycle for as long as the pill is helpful
-Have an MRI scan of your brain every 8 weeks
-Have a clinic visit of days 1 and 15 of your cycle for the first 2 cycles
---After the first 2 cycles you will only come to the clinic on the first day of your cycle

*If a person taking the placebo has growth of their tumor while in the study, they may have the option to be given the active AG881 drug.